Investing

Top Day Trader Alerts (AMZN, ARNA, BP, NTY, OREX, VRNM, VVUS)

There are many stocks on the move for day traders and active traders this Tuesday morning now that earnings season has launched.

Amazon.com Inc. (NASDAQ: AMZN) is trading lower after Bank of America/Merrill Lynch cut the rating to NEUTRAL from BUY.  Shares are down 2.3% at $120.40 on over 60,000 shares, but the stock was challenging $119 earlier.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is up as a VIVUS-FDA side trade stock.  Shares are up 10% at $4.72 on over 300,000 shares.

BP plc (NYSE: BP) is down about 1% this morning after it delayed well-cap tests at the Gulf of Mexico disaster until later Wednesday.  This morning the oil flows freely.

NBTY Inc. (NYSE: NTY) is surging by 44% to $54.12 after receiving a $3 billion takeover from private equity for the vitamin and supplements operation.  We have already seen close to 6 million shares traded.

Orexigen Therapeutics, Inc. (NASDAQ: OREX) is also trading higher on the VIVUS drug class tie ahead of its FDA panel decision today.  Shares are up 2.4% at $5.69 on almost 30,000 shares.

Verenium Corporation (NASDAQ: VRNM) is trading up massively after getting a biofuels deal for $98 million for its units from BP.  This was a $30 million company, and shares were up 81% at $4.47 on 20,000 shares.

VIVUS, Inc. (NASDAQ: VVUS) SHARES ARE HALTED…. The company has its Qnexa FDA panel decision due today… stay tuned.

JON C. OGG

Want to Retire Early? Start Here (Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.